2020 Highlights


We started 2020 by announcing strong full-year 2019 results.


We strengthened our Executive Committee with the appointment of new Chief Human Resources Officer (CHRO) Caroline Barth, who joined Lonza in May.


We reported a solid Q1 financial performance, despite a challenging environment early on in the pandemic, during an unscheduled investor update.

We successfully placed our inaugural Eurobond with a value of EUR 500 million.


We entered into a landmark ten-year collaboration agreement with Moderna Inc. to manufacture the drug substance for Moderna’s COVID-19 Vaccine, alongside other mRNA-based collaboration projects from Moderna’s innovation pipeline.


We expanded our global particle engineering network and added new dedicated development capacity for spray dry processing.

We reported strong operational performance maintained during COVID-19, with Pharma Biotech business driving group sales growth and margin improvement in H1 2020. In addition, the Board of Directors reviewed strategic options for the long-term future of the LSI business and decided to divest the LSI segment via a sale process.

We announced that our Ibex® Dedicate facility will support the commercial manufacture of Kodiak’s KSI-301 - an Antibody Biopolymer Conjugate (ABC) for retinal diseases.


We expanded our microbial manufacturing facility in Visp (CH) and extended the long-term partnership with Servier for L-asparaginase API manufacturing.


We qualified the Cocoon® Platform towards clinical and commercial readiness and treated the first patient at Sheba Medical Center (IL) with an autologous CAR-T therapy, manufactured using the Cocoon® Platform.


We provided details of our new structural design, cultural values and external reporting during Investor Update event.

We announced an expansion of our capsule manufacturing capacity.

We announced an agreement to manufacture AstraZeneca’s COVID-19 long-acting antibody combination.

Our Diversity and Inclusion global taskforce lead team was formed.


We welcomed new Group Chief Executive Officer (CEO) Pierre-Alain Ruffieux.

We announced an expansion of our highly potent drug product development and manufacturing capabilities in Tampa (USA), as well as our particle engineering and drug product capabilities in Bend (USA).


We announced the construction of two new customer-dedicated conjugation suites for the commercialization of ADC in Ibex® Dedicate, Visp (CH).